Geron Corp (GERN) option IV into FDA Oncologic Drugs Advisory Committee meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs
March 15, 2024 3:51 AM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Geron Corporation (NASDAQ: GERN) to $5.00 (from $4.00) while maintaining a Buy rating.
The analyst comments "
We expect GERN to trade higher tomorrow (+85-90% in after hours trading) following the FDA's Advisory... More
